Kidney Disease May Soon Be Reversible—Here's What's Changing

For the first time in medical history, scientists have found ways to reverse kidney damage rather than just slow its progression. New treatments using diabetes medications like Ozempic and Mounjaro are helping patients move from near-kidney failure back to manageable disease stages, fundamentally changing what's possible for the 700 million people worldwide living with chronic kidney disease (CKD).

How Are Doctors Actually Reversing Kidney Damage?

The breakthrough centers on two classes of drugs originally developed for Type 2 diabetes. Nicolas Palacios experienced this transformation firsthand—diagnosed with Stage 4 kidney disease at age 28, he was on the verge of needing dialysis or a transplant. After joining a clinical trial testing tirzepatide (Mounjaro), his kidney function improved so dramatically that he's now classified as having Stage 3 kidney disease, meaning he can live a long, healthy life without ever needing dialysis.

"In my 40 years being a nephrologist, I never saw patients [improve like Palacios]," says Katherine Tuttle, a researcher at the University of Washington. "And he's not the only one."

What Makes These New Treatments So Effective?

Two main drug classes are driving these remarkable results:

• SGLT2 Inhibitors: These medications stop the kidneys from reabsorbing glucose, which appears to give kidney cells more energy to respond to injury and adapt better. Many trials were stopped early because the results were so dramatically positive.
• GLP-1 Receptor Agonists: Drugs like semaglutide (Ozempic) and tirzepatide (Mounjaro) are showing the ability to reprogram how organs work at a molecular level. A 2024 Phase 3 trial with semaglutide was ended early because kidney failure and death rates were so much lower in treated patients.
• Combination Approaches: The CONFIDENCE trial showed that starting finerenone and empagliflozin simultaneously was more effective than either drug alone, supporting early, proactive treatment strategies.

The Food and Drug Administration (FDA) approved semaglutide for chronic kidney disease in 2025, showing a 24% relative risk reduction compared to placebo when added to standard therapy. These approvals mark a shift toward precision-driven, mechanism-based treatments rather than one-size-fits-all approaches.

What Does This Mean for Patients Today?

Beyond reversing damage, researchers are tackling the entire spectrum of kidney care. For patients with IgA nephropathy, the most common form of glomerulonephritis, new targeted therapies like atrasentan received FDA accelerated approval in 2025, representing the first selective endothelin A receptor antagonist for this condition.

Even more futuristic treatments are entering human trials. The FDA cleared the first clinical trials for genetically modified pig kidney transplants in 2025, with the EXPAND trial beginning at NYU Langone Health. This xenotransplantation approach could eventually address the critical organ shortage—over 103,000 people are currently waiting for kidney transplants.

For dialysis patients, innovations like the Holly system, an implantable dialysis device designed to work continuously inside the body, received FDA Breakthrough Device Designation. Researchers are also developing portable dialysis devices as small as smartphones that would be powered by the patient's own blood pressure.